News
June 08, 2010
Intercell completed the acquisition of Cytos' antibody technology platform
Vienna (Austria), June 8, 2010 – Intercell AG (VSE: ICLL) today announced the closing of the acquisition of Cytos' platform technology for monoclonal antibody discovery. On May 6, 2010 Intercell had announced the intent to acquire that technology, which is based on expression cloning of monoclonal antibodies from human B-cells, for EUR 15m.
The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®).
Download
Please click on the link to download the press release: